Trial Profile

A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered Orally in Healthy Male Adult Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PXS-5382A (Primary)
Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Renal fibrosis
Focus Adverse reactions
Sponsors Pharmaxis; Synairgen; Syntara Limited

Most Recent Events

04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
15 Nov 2018 Results published in the Media Release
14 Nov 2018 Status changed from active, no longer recruiting to completed, according to an Arix Bioscience media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com